Original Paper: Gastro-oesophageal reflux disease in primary care Comparison and evaluation of existing national guidelines and development of uniform European guidelines

References

• Ruth M, Mansson I, Sandberg N. The prevalence of symptoms suggestive of esophageal disorders. Scand J Gastroenterol 1991; 26: 73–81
   PubMed Web of Science ®Google Scholar
• Locke G R, Talley N J, Fert S L, Zinsmeister A R, Melton L J. Prevalence and clinical spectrum of gastroesophageal reflux: a population based study in Olmsted County, Minnesota. Gastroenterology 1997; 112: 1448–56
   PubMed Web of Science ®Google Scholar
• Heading R C. Epidemiology of oesophageal reflux disease. Scand J Gastroenterol 1989; 24(Suppl 168)33–7
   PubMed Web of Science ®Google Scholar
• Johnsson F, Joelsson K, Gudmundsson K, Greiff L. Symptoms and endoscopic findings in the diagnosis of gastroesophageal reflux disease. Scand J Gastroenterol 1987; 22: 714–8
   PubMed Web of Science ®Google Scholar
• Klauser A G, Heinrich C, Schindlbeck N E, Müller-Lissner S A. Is long-term esophageal pH monitoring of clinical value?. Am J Gastroenterol 1989; 84(4)362–6
   PubMed Web of Science ®Google Scholar
• Bolin T D, Tytgat G NJ. Dyspepsia and esophageal reflux: an overview. Scand J Gastroenterol 1995; 210(Suppl)43–4
   Google Scholar
• Talley N J, Colin-Jones D, Koch K L, Nyrén O, Stanghellini V. Functional dyspepsia: a classification with guidelines for diagnosis and management. Gastroenterol Int 1991; 4: 145–60
   Google Scholar
• Eggleston A, Wigerinck A, Huijghebaert S, Dubois D, Haycox A. Cost effectiveness of treatment for gastro-oesophageal reflux disease in clinical practice: a clinical database analysis. Gut 1998; 42: 13–6
   PubMed Web of Science ®Google Scholar
• Nyrén O, Adami H O, Gustavsson S, Loof L, Nyberg A. Social and economic effects of non-ulcer dyspepsia. Scand J Gastroenterol 1985; 20(Suppl 109)41–7
   Google Scholar
• Fennerty M B, Castell D O, Fendrick A M, Halpern M, Johnson D, Kahrilas P J, et al. The diagnosis and treatment of gastroesophageal reflux disease in a managed care environment. Arch Intern Med 1996; 156(5)477–84
   PubMedGoogle Scholar
• Weinberg D S, Kadish S L. The diagnosis and management of gastroesophageal reflux disease. Med Clin North Am 1996; 80(2)411–29
   PubMedGoogle Scholar
• DeVault K R, Castell D O. Guidelines for the diagnosis and treatment of gastroesophageal reflux disease. Practice Parameters Committee of the American College of Gastroenterology. Arch Intern Med 1995; 155(20)2165–73
   PubMedGoogle Scholar
• Castell D O, Johnston B T. Gastroesophageal reflux disease. Current strategies for patient management. Arch Fam Med 1996; 5(4)221–7
   PubMedGoogle Scholar
• Klauser A G, Schindlbeck N E, Müller-Lissner S A. Symptoms in gastro-oesophageal reflux disease. Lancet 1990; 335: 205–8
   PubMed Web of Science ®Google Scholar
• Numans M E. Determinants of relevant diagnoses in open access gastroscopy [diesis/dissertation]. University of Utrecht. 1992; 165–88
   Google Scholar
• Adang R P, Ambergen A W, Talmon J L, Hasman A, Vismans J F, Stockbrugger R W. The discriminative value of patient characteristics and dyspeptic symptoms for upper gastrointestinal endoscopic findings: a study on the clinical presentation of 1,147 patients. Digestion 1996; 57: 118–34
   PubMedGoogle Scholar
• Talley N J, Weaver A L, Tesmer D L, Zinsmeister A R. Lack of discriminant value of dyspepsia subgroups in patients referred for upper endoscopy. Gastroenterology 1993; 105: 1378–86
   PubMed Web of Science ®Google Scholar
• Stevenson G W, Norman G, Frost R, Somers S. Barium meal or endoscopy? A prospective randomized study of patient preference and physician decision making. Clin Radiol 1991; 44: 317–21
   PubMedGoogle Scholar
• Dooley C P, Weiner J M, Larson A W. Endoscopy or radiography; the patient's choice. Ann Intern Med 1986; 80: 203–7
   Google Scholar
• Martin T R, Vermes J A, Silvis S E, Ansel H J. A comparison of upper gastrointestinal endoscopy and radiography. J Clin Gastroenterol 1980; 2: 21–5
   PubMed Web of Science ®Google Scholar
• Shaw P C, Romunde L K, Griffioen G, Janssens A R, Kreuning J, Eil-Ers G A. Peptic ulcer and gastric carcinoma: diagnosis with biphasic radiography compared with fiberoptic endoscopy. Radiology 1987; 163: 39–42
   PubMedGoogle Scholar
• Dooley C P, Larson A W, Stace N H, Renner I G, Valenzuela J E, Eliasoph J, et al. Double-contrast barium meal and upper gastrointestinal endoscopy: a comparative study. Ann Intern Med 1984; 101: 538–45
   PubMed Web of Science ®Google Scholar
• Ott D J. Gastroesohageal reflux: What is the role of barium studies?. Am J Roentgenol 1994; 162: 627–9
   PubMedGoogle Scholar
• Johannessen T, Petersen H, Kleveland P M, Dybdahl J H, Sandvik A K, Brenna E, et al. The predictive value of history in dyspepsia. Scand J Gastroenterol 1990; 25: 689–97
   PubMed Web of Science ®Google Scholar
• Adang R P, Vismans J F, Talmon J L, Hasman A, Ambergen A W, Stockbrügger R W. The diagnostic outcome of upper gastrointestinal endoscopy: are referral source and patient age determining factors?. Eur J Gastroenterol Hepatol 1994; 6: 329–35
   Google Scholar
• Williams B, Luckas M, Ellingham J HM, Dam A, Wicks A CB. Do voting patients with dyspepsia need investigation?. Lancet 1988; 11: 1349–51
   Google Scholar
• Kerrigan D D, Brown S R, Hutchinson G H. Open access gastroscopy: too much to swallow?. Br Med J 1990; 300: 374–6
   PubMedGoogle Scholar
• Kitchin L I, Castell D O. Rationale and efficacy of conservative therapy for gastroesophageal reflux disease. Arch Intern Med 1991; 151: 448–54
   PubMedGoogle Scholar
• Bytzer P, Hansen J M, Schaffalitzski D E, Muckadell O B. Empirical H2-blocker therapy or prompt endoscopy in management of dyspepsia. Lancet 1994; 343: 811–6
   PubMed Web of Science ®Google Scholar
• Schenk B E, Kuipers E J, Klinkenberg-Knol E C, Festen H PM, Jansen E H, Tuynman H A, et al. Omeprazole as a diagnostic tool in gastroesophageal reflux disease [see comments]. Am J Gastroenterol 1997; 92(11)1997–2000
   PubMedGoogle Scholar
• Schindlbeck N E, Klauser A G, Voderholzer W A, Müller-Lissner S A. Empiric therapy for gastroesophageal reflux disease. Arch Intern Med 1995; 155(16)1808–12
   PubMedGoogle Scholar
• Johnsson F, Weyvvadt L, Solhaug J H, Hernqvist H, Bengtsson L. One-week omeprazole treatment in the diagnosis of gastro-esophageal reflux disease. Scand J Gastroenterol 1998; 33: 15–20
   PubMed Web of Science ®Google Scholar
• Fass R, Fennerty M B, Yalam J M, Camargo L, Garewall H, Grade A, et al. Evaluation of the ‘omeprazole test’ in patients with typical symptoms of reflux disease. Gastroenterology 1997; 112, Abstract 114.
   Google Scholar
• Kahrilas P J. Treatment versus management of gastroesophageal reflux disease (comment). Am J Gastroenterol 1997; 92(11)1959–60
   PubMedGoogle Scholar
• Mason I, Millar L J, Sheikh R R, Evans W MI, Todd P L, Turbitt M L, et al. The management of acid-related dyspepsia in general practice: a comparison of an omeprazole versus an antacid-alginate/ranitidine management strategy. Aliment Pharmacol Ther 1998; 12: 263–71
   PubMedGoogle Scholar
• Goves J, Oldring J K, Kerr D, Dallara R G, Roffe E J, Taylor M D. First line treatment with omeprazole provides an effective and superior alternative strategy in the management of dyspepsia compared to antacid/alginate liquid: a multicentre study in general practice. Aliment Pharmacol Ther 1998; 12: 147–57
   PubMedGoogle Scholar
• Venables T L, Newland R D, Patel A C, Hole J, Wilcock C, Turbitt M L. Omeprazole 10 milligrams once daily, omeprazole 20 milligrams once daily, or ranitidine 150 milligrams twice daily, evaluated as initial therapy for the relief of symptoms of gastro-oesophageal reflux disease in general practice. Scand J Gastroenterol 1997; 32: 965–73
   PubMed Web of Science ®Google Scholar
• Chiba N, de Cara C J, Wilkinson J M, Hunt R H. Speed of healing and symptom relief in grade II to IV gastro-oesophageal reflux disease. Gastroenterology 1997; 112: 1798–810
   PubMed Web of Science ®Google Scholar
• Bate C M, Griffin S M, Keeling P WN, Axon A TR, Dronfield M W, Chapman R WG. Reflux symptom relief with omeprazole in patients without unequivocal oesophagitis. Aliment Pharmacol Ther 1996; 10: 547–55
   PubMed Web of Science ®Google Scholar
• Eriksson S, Langstrom G, Rikner L, Carlsson R, Naesdel J. Omeprazole and H2-receptor antagonists in the acute treatment of duodenal ulcer, gastric ulcer and reflux oesophagitis: a meta-analysis. Eur J Gastroenterol Hepatol 1995; 7: 467–75
   PubMed Web of Science ®Google Scholar
• Hungm A PS, Gunn S D, Bate C M, Turbitt M L, Wilcock C, Richardson P DI. A comparison of the efficacy of omeprazole 20 nig once daily with ranitidine 150 mg bd in the relief of symptomatic gastro-oesophageal reflux disease in general practice. Br J Clin Res 1993; 4: 73–88
   Google Scholar
• Klinkenberg-Knol E C, Festen H PM, Meuwissen S GM. Pharmacological management of gastro-oesophageal reflux disease. Drugs 1995; 49(5)695–710
   PubMedGoogle Scholar
• Galmiche J P, Fraitag B, Filoche B, Evreux M, Vitaux J, Zeitoun P, et al. Double blind comparison of cisapride and cimetidine in treatment of reflux esophagitis. Dig Dis Sci 1990; 35: 649–55
   PubMed Web of Science ®Google Scholar
• Janish H D, Hütteman W, Bouzo M H. Cisapride versus ranitidine in the treatment of reflux oesophagitis. Hepatogastroenterol 1988; 35: 125–7
   PubMedGoogle Scholar
• Evreux M, Filoche B, et al. Endoscopic and clinical evaluation of cisapride and cimetidine in reflux oesophagitis. Gastroenterology 1988; 94, Abstract 120.
   Google Scholar
• Maleev A, Mendizova A, Popov P, et al. Cisapride and cimetidine in the treatment of erosive esophagitis. Hepatogastroenterol 1990; 37: 403–7
   PubMedGoogle Scholar
• Lind T, Havelund T, Carlsson R, Anker-Hansen O J, Glise H, Hernqvist H, et al. Heartburn without oesophagitis: efficacy of omeprazole therapy and features determining therapeutic response. Scand J Gastroenterol 1997; 32: 974–9
   PubMed Web of Science ®Google Scholar
• Carlsson R, Dent J, Watts R, Riley S, Sheikh R R, Hatlebakk J, et al. Gastro-oesophageal reflux disease in primary care: an international study of different treatment strategies with omeprazole. International CORD Study Group. Eur J Gastroenterol Hepatol 1998; 10(2)119–24
   PubMedGoogle Scholar
• Tytgat G NJ, Anker-Hansen O J, Carling L, deGroot G, Geldof H, Glise H, et al. Effect of cisapride on relapse of reflux oesophagitis, healed with an antisecretory drug. Scand J Gastroenterol 1992; 27: 175–83
   PubMed Web of Science ®Google Scholar
• Toussaint J, Gossuin A, Deruyterre M, Huble F, Devis G. Healing and prevention of relapse reflux oesophagitis by cisapride. Gut 1991; 32: 1280–5
   PubMed Web of Science ®Google Scholar
• Koelz H R, Birchler R, Bretzholz A, et al. Healing and relapse of reflux esophagitis during treatment with ranitidine. Gastroenterology 1986; 91: 1198–205
   PubMed Web of Science ®Google Scholar
• Hetzel D J, Dent J, Reed W D, et al. Healing and relapse of severe peptic oesophagitis after treatment with omeprazole. Gastroenterology 1988; 95: 903–12
   PubMed Web of Science ®Google Scholar
• Lundell L, Backman L, Ekstrom P, et al. Omeprazole or high dose ranitidine in the treatment of patients with reflux oesophagitis not responding to standard doses of H, receptor antagonists. Aliment Pharmacol Ther 1990; 4: 145–50
   PubMed Web of Science ®Google Scholar
• Carlsson R, Galmiche J P, Dent J, Lundell L, Frison L. Prognostic factors influencing relapse of oesophagitis during maintenance therapy with antisecretory drugs: a meta-analysis of long term omeprazole trials. Aliment Pharmacol Ther 1997; 11: 473–82
   PubMedGoogle Scholar
• Bate C M, Crowe J P, Dickinson R J, Green J RB, Banarjee S, Dronfield M W, et al. Reflux oesophagitis resolves more rapidly with omeprazole 20 mg once daily than with ranitidine 150 mg twice daily: omeprazole 40 mg once daily provides further benefit in unresponsive patients. Br J Clin Res 1991; 2: 133–48
   Google Scholar
• Vigneri S, Termini R, Leandro G, Badalamenti S, Pantalena M, Savarino V, et al. A comparison of five maintenance therapies for reflux oesophagitis. N Engl J Med 1995; 333: 1106–10
   PubMed Web of Science ®Google Scholar
• Lundell L, Backman L, Ekstrom P, Enander L K, Falkmer S, Fausa O, et al. Prevention of relapse of reflux oesophagitis after endoscopic healing: the efficacy and safety of omeprazole compared with ranitidine. Scand J Gastroenterol 1991; 26: 248–56
   PubMed Web of Science ®Google Scholar
• Dent J, Yeomans N D, Mackinnon M, Reed W D, Narielvala F M, Hetzel D J, et al. Omeprazole v ranitidine for prevention of relapse in reflux oesophagitis: a controlled double blind trial of their efficacy and safety. Gut 1994; 35: 590–8
   PubMed Web of Science ®Google Scholar
• Hallerbäck B, Unge P, Carling L, Edwin B, Glise H, Havu N, et al. Omeprazole or ranitidine in long-term treatment of reflux oesophagitis. Gastroenterology 1995; 107: 1305–11
   Web of Science ®Google Scholar
• Hillman A, Bloom B S, Fendrick A M, Schwartz J S. Cost and quality-effects of alternative treatments for persistent gastroesophageal reflux disease. Arch Intern Med 1992; 152: 1467–72
   PubMedGoogle Scholar
• Bate C M, Richardson P DI. A one year model for the cost effectiveness of treating reflux oesophagitis. Br J Med Econ 1992; 2: 5–11
   Google Scholar
• Hamelin A, Arnould B, Barbier P, et al. Cost-effectiveness comparison between omeprazole and ranitidine for treatment of reflux oesophagitis. Gastroenterology 1994; 106, Abstract 88
   PubMedGoogle Scholar
• Bardhan K D, Müller-Lissner S A, Bigard M A, Bianchi-Porro G, Ponce J, Hosie J, et al. Symptomatic gastro-oesophageal reflux disease: intermittent treatment with omeprazole and ranitidine as a strategy for management. Gastroenterology 1997; 112(Suppl 4), Abstract 165.
   Google Scholar
• Isal J P, Zeitoun P, Barbier P, Cayphas J P, Carlsson R. Comparison of two dosage regimens of omeprazol - 10 mg daily and 20 mg weekends as prophylaxis against recurrence of reflux oesophagitis. Gastroenterology 1990; 98, Abstract 63.
   Google Scholar
• Bardhan K D, Daly M J, Singh S, Morris P, Thompson M, Hinchcliffe R FC. Refractory erosive oesophagitis; result of maintenance treatment with high dose H,-receptor antagonists or omeprazole. Gut 1990; 31, Abstract602.
   PubMedGoogle Scholar
• Blum A L, Adami B, Bouzo M H, et al. Effect of cisapride on relapse of esophagitis: a multinational, placebo-controlled trial in patients healed with an antisecretory drug. Dig Dis Sci 1993; 38: 551–60
   PubMed Web of Science ®Google Scholar
• Silveira J CB, Barbosa J, Barreiros J, Beija B, Ferreira L SA, Freitas J, et al. Cisapride versus ranitidine in the treatment and prevention of recurrent oesophagitis. Hellenic J Gastroenterol 1992; 5(Suppl)324
   Google Scholar
• Klinkenberg-Knol E C, Festen H PM, Jansen J BMJ, et al. The efficacy and safety of long term treatment with omeprazole of patients with refractory reflux esophagitis. Ann Intern Med 1994; 121: 161–7
   PubMed Web of Science ®Google Scholar
• Koop H, Arnold R. Long-term maintenance treatment of reflux esophagitis with omeprazole. Dig Dis Sci 1991; 36: 552–7
   PubMedGoogle Scholar
• Lamberts R, Creutzfeldt W, Struber H G, et al. Long-term omeprazole therapy in peptic ulcer disease: gastrin, endocrine cell growth, and gastritis. Gastroenterology 1993; 104: 1356–70
   PubMed Web of Science ®Google Scholar
• Kuipers E J, Lundell L, Klinkenberg-Knol E C, Havu N, Festen H PM, Liedman B, et al. Atrophic gastritis and Helicobacter pylori infection in patients with reflux esophagitis treated with omeprazole or fun-doplication. N Engl J Med 1996; 334: 1018–22
   PubMed Web of Science ®Google Scholar
• Josefson D. FDA warns about heartburn drug. Br Med J 1998; 317: 101
   PubMedGoogle Scholar